Canada Life
AXSM icon

Canada Life’s Axsome Therapeutics AXSM Stock Holding History

Canada Life’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
4,274
+267
+7% +$57.9K ﹤0.01% 1355
2026
Q1 		$680K Hold
4,007
– – ﹤0.01% 1441
2025
Q4 		$732K Sell
4,007
-4,984
-55% -$696K ﹤0.01% 1443
2025
Q3 		$1.06M Buy
8,991
+1,586
+21% +$179K ﹤0.01% 1428
2025
Q2 		$775K Buy
7,405
+4,293
+138% +$455K ﹤0.01% 1500
2025
Q1 		$364K Hold
3,112
– – ﹤0.01% 1661
2024
Q4 		$263K Sell
3,112
-239
-7% -$22K ﹤0.01% 1726
2024
Q3 		$301K Sell
3,351
-4,248
-56% -$371K ﹤0.01% 1757
2024
Q2 		$611K Buy
7,599
+229
+3% +$17K ﹤0.01% 1632
2024
Q1 		$588K Buy
7,370
+4,258
+137% +$357K ﹤0.01% 1652
2023
Q4 		$246K Hold
3,112
– – ﹤0.01% 1807
2023
Q3 		$217K Buy
3,112
+1,700
+120% +$127K ﹤0.01% 1842
2023
Q2 		$102K Sell
1,412
-129
-8% -$9.52K ﹤0.01% 1924
2023
Q1 		$95K Hold
1,541
– – ﹤0.01% 1985
2022
Q4 		$119K Hold
1,541
– – ﹤0.01% 1959
2022
Q3 		$69K Hold
1,541
– – ﹤0.01% 2050
2022
Q2 		$59K Hold
1,541
– – ﹤0.01% 2023
2022
Q1 		$68K Hold
1,541
– – ﹤0.01% 2089
2021
Q4 		$58K Hold
1,541
– – ﹤0.01% 2134
2021
Q3 		$51K Hold
1,541
– – ﹤0.01% 2229
2021
Q2 		$104K Sell
1,541
-514
-25% -$30.8K ﹤0.01% 2081
2021
Q1 		$115K Hold
2,055
– – ﹤0.01% 2067
2020
Q4 		$167K Hold
2,055
– – ﹤0.01% 2008
2020
Q3 		$146K Hold
2,055
– – ﹤0.01% 1960
2020
Q2 		$168K Buy
2,055
+445
+28% +$34.3K ﹤0.01% 1946
2020
Q1 		$96K Hold
1,610
– – ﹤0.01% 1985
2019
Q4 		$165K Buy
+1,610
New +$65K ﹤0.01% 1967
2019
Q3 		– Sell
-3,035
Closed -$78K – 1227
2019
Q2 		$78K Buy
+3,035
New +$60.8K ﹤0.01% 2302

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Canada Life's AXSM Position: Q2 2026 in Review

Canada Life increased its Axsome Therapeutics (AXSM) stake by 6.7% in Q2 2026, buying an estimated $57.9K and bringing the position to 4,274 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Canada Life first reported a position in AXSM in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.06M in Q3 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Canada Life held 4,274 shares of Axsome Therapeutics worth $1.04M as of Q2 2026.
  • Canada Life bought 267 Axsome Therapeutics shares in Q2 2026, an estimated $57.9K.
  • Axsome Therapeutics made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1355 holding.
  • Canada Life first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Canada Life's Axsome Therapeutics position peaked at $1.06M in Q3 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.